Change in topoisomerase 1 (Top1) positive circulating tumor cells impacts overall survival in patients with advanced breast cancer after treatment with etirinotecan pegol.

CONCLUSIONS: CTC Top1 expression following EP treatment may identify patients with MBC most likely to have an OS benefit.
PMID: 29618616 [PubMed - as supplied by publisher]

Source: Clinical Cancer Research - April 4, 2018 Category: Cancer & Oncology Authors: Rugo HS, Cortes J, Awada A, O'Shaughnessey J, Twelves CJ, Im SA, Hannah A, Lu L, Sy S, Caygill K, Zajchowski DA, Davis DW, Tagliaferri MA, Hoch U, Perez EA Tags: Clin Cancer Res Source Type: research